Coherus Biosciences Inc. expanded the horizons for its biosimilar product for Enbrel (etanercept, Amgen Inc.) by inking a potential $246 million deal giving Baxter International Inc. rights to the drug in Europe, Canada, Brazil and other undisclosed markets.